摘要
目的探讨血清白细胞介素6,8,18(IL-6,IL-8,IL-18)与肺癌的发生、发展、转移、疗效及预后的关系。方法采用双抗体夹心酶联免疫吸附试验(ELISA法)检测56例肺癌患者、18例肺结核患者治疗前后及40例健康人的血清IL-6,IL-8,IL-18含量,并进行比较分析。结果肺癌患者血清IL-6,IL-8,IL-18水平明显高于正常人和肺结核患者(P<0.01),且与临床分期及治疗效果有关(P<0.05或<0.01),与病理类型无关(P>0.05)。结论血清IL-6,IL-8,IL-18水平在一定程度上可反映肺癌发生、发展、转移情况及治疗效果,联合检测IL-6,IL-8,IL-18,对肺癌的诊断、治疗及预后评价有重要意义。
Objective To study the relationships between serum interleukin-6, 8, 18 and the development, metastasis, curative effect and prognosis of lung cancer. Methods The serum interleukin-6, 8, 18 in 56 cases patients with lung cancer, 18 cases patients with phthisis were determined by ELISA method before and after treatment, and 40 cases health people were control. Results The serum interleukin-6, 8, 18 level of patients with lung cancer was significantly higher than that in control groups and the patients with phthisis （P 〈0.01 ）, and correlated with clinical stages and curative effect（P 〈0.05 or 0.01 ）, Being foreign to pathology stages（P 〉0.05）. Conclusion The serum interleukin-6, 8, 18 levels could reflected occurrence, development, metastasis and curative effect of the lung cancer in a certain extent, so it was importance for diagnosis, treatment and prognosis of lung cancer to combine examination IL-6, 8, 18.
出处
《肿瘤研究与临床》
CAS
2006年第11期739-741,共3页
Cancer Research and Clinic
作者简介
周志伟，男，学士，主任，副主任医师。
